Guido Finazzi

Q: What Schools Are Affiliated With Guido Finazzi

Guido Finazzi is affiliated with the following schools: University of Milan, University of Oxford, University of Florence, University of Bologna, University of Vienna, Leiden University

Guido Finazzi's AcademicInfluence.com Rankings

Guido Finazzi

Philosophy

#9006

World Rank

#12496

Historical Rank

Logic

#6014

World Rank

#7489

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Guido Finazzi's Degrees

PhD Biomedical Sciences University of Milan
Doctorate Medicine University of Milan

Why Is Guido Finazzi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Guido Finazzi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. (2007) (893)
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. (1995) (790)
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. (2011) (745)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. (2005) (633)
Cardiovascular events and intensity of treatment in polycythemia vera. (2013) (621)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. (2014) (552)
The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. (1997) (528)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study (2013) (506)
Inherited thrombophilia: pathogenesis, clinical syndromes, and management. (1996) (474)
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) 1 (2005) (457)
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. (2007) (454)
Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. (1990) (448)
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. (1996) (444)
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). (2012) (424)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. (2005) (403)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. (2007) (366)
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. (2011) (365)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet (2018) (342)
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments (2008) (325)
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. (2007) (306)
Myeloproliferative neoplasms and thrombosis. (2013) (303)
A pilot study of the Histone‐Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms (2010) (235)
High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. (1991) (228)
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. (2009) (227)
Thrombosis in primary myelofibrosis: incidence and risk factors. (2009) (213)
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial (2000) (209)
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. (2013) (200)
Defibrotide for the treatment of hepatic veno‐occlusive disease: results of the European compassionate‐use study (2000) (195)
Leukocytosis and risk stratification assessment in essential thrombocythemia. (2007) (192)
The haematocrit and platelet target in polycythemia vera (2007) (186)
Thrombotic and Hemorrhagic Complications in Patients with Mechanical Heart Valve Prosthesis Attending an Anticoagulation Clinic (1993) (173)
Different Prevalence of Thromboembolism in the Subtypes of Congenital Antithrombin III Deficiency:Review of 404 Cases (1987) (172)
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). (2011) (170)
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera (2000) (169)
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. (2007) (167)
Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. (1995) (165)
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia (2015) (165)
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 (2011) (162)
Clinical Manifestations and Management of Inherited Thrombophilia: Retrospective Analysis and Follow-up after Diagnosis of 238 Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S (1994) (161)
Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? (2009) (150)
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. (1999) (150)
Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. (1984) (148)
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. (2011) (148)
The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera. (2006) (145)
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. (2007) (145)
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process (2010) (143)
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria (2012) (139)
How I treat patients with polycythemia vera. (2007) (131)
The Impact of All-trans-Retinoic Acid on the Coagulopathy of Acute Promyelocytic Leukemia (1998) (123)
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. (2000) (120)
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. (1998) (119)
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy (2013) (118)
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. (2008) (115)
Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. (2008) (110)
Hydroxyurea‐related toxicity in 3,411 patients with Ph'‐negative MPN (2012) (109)
Chronic myeloproliferative disorders. (2003) (107)
Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofibrosis may be due to the action of a number of proteases. (2005) (105)
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (104)
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia (2008) (104)
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. (2014) (103)
The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances. (2016) (98)
Markers of Procoagulant Imbalance in Patients with Inherited Thrombophilic Syndromes (1992) (98)
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. (2009) (97)
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. (2012) (89)
The Italian Registry of Antiphospholipid Antibodies. (1997) (81)
A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. (2000) (79)
Antiphospholipid antibodies in early repeated abortions: a case-controlled study. (1988) (78)
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment (2009) (78)
Thrombosis in Cancer Patients Treated with Hematopoietic Growth Factors - A Meta-Analysis (1996) (76)
Risk-adapted therapy in essential thrombocythemia and polycythemia vera. (2005) (75)
White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. (2015) (75)
When and how to treat essential thrombocythemia. (2005) (74)
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. (2014) (72)
Severe bleeding due to acquired hypoprothrombinemia-lupus anticoagulant syndrome. Case report and review of literature. (1997) (72)
Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). (1999) (72)
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients (2016) (71)
Coinheritance of the HR2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R506Q (Factor V Leiden) (1999) (71)
Inherited protein C deficiency and nonhemorrhagic arterial stroke in young adults (1991) (69)
The Risk of Thrombosis in Patients with Lupus Anticoagulants Is Predicted by their Specific Coagulation Profile (1999) (67)
A prospective analysis of thrombotic events in the European collaboration study on low-dose aspirin in polycythemia (ECLAP). (2004) (66)
Thrombocytopenia in the antiphospholipid syndrome (1996) (66)
Diagnosis and Treatment of Polycythemia Vera and Possible Future Study Designs of the PVSG (2000) (66)
Different Incidence of Venous Thrombosis in Patients with Inherited Deficiencies of Antithrombin III, Protein C and Protein S (1994) (65)
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. (2012) (64)
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. (1999) (64)
Masked polycythemia vera diagnosed according to WHO and BCSH classification (2014) (64)
Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Italian Registry of Antiphospholipid Antibodies (IR-APA). (1993) (64)
Clinical parameters for determining when and when not to treat essential thrombocythemia. (1999) (64)
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria. (2010) (63)
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. (2003) (63)
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists (2016) (63)
Diagnosis of essential thrombocythemia at platelet counts between 400 and 600x10(9)/L. Gruppo Italiano Malattie Mieloproliferative Croniche(GIMMC). (2000) (59)
The constitutive mobilization of bone marrow-repopulating cells into the peripheral blood in idiopathic myelofibrosis. (2005) (59)
JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. (2011) (58)
Masked polycythemia Vera (mPV): Results of an international study (2013) (58)
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia (2009) (57)
Masked polycythemia Vera (mPV): Results of an international study (2014) (56)
Identification of nine novel mutations in type I antithrombin deficiency by heteroduplex screening (1993) (55)
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. (1996) (54)
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study (2019) (54)
Diagnosis of Mycobacterium bovis infection in calves sensitized by mycobacteria of the avium/intracellulare group. (2002) (52)
Myeloproliferative disease in pregnancy and other management issues. (2006) (52)
Leukocytosis as an important risk factor for arterial thrombosis in WHO‐defined early/prefibrotic myelofibrosis: An international study of 264 patients (2012) (51)
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group (2007) (51)
Phospholipid‐dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia (2014) (51)
Antiphospholipid Antibodies: Predictive Value of Laboratory Tests (1997) (51)
Treatment of polycythemia vera. (1998) (50)
Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis (2013) (50)
The G1691 → A mutation of factor V, but not the G20210 → A mutation of factor II or the C677 → T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants (2000) (50)
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia (2014) (50)
The CYTO-PV: A Large-Scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (2011) (49)
HEREDITARY DYSFUNCTIONAL PROTEIN C (PROTEIN C BERGAMO) AND THROMBOSIS (1984) (47)
Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. (1996) (47)
Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. (1993) (47)
Front-line therapy in polycythemia vera and essential thrombocythemia. (2012) (47)
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases (2018) (47)
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera (2014) (46)
A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched study (2017) (46)
Sale of raw milk in northern Italy: food safety implications and comparison of different analytical methodologies for detection of foodborne pathogens. (2012) (44)
The effect of arterial hypertension on thrombosis in low‐risk polycythemia vera (2017) (44)
Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrate (1991) (44)
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) (2014) (43)
Treatment of essential thrombocythemia with special emphasis on leukemogenic risk (1999) (42)
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation (2010) (42)
Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms (2017) (40)
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. (2012) (40)
Recurrence after first cerebral infarction in young adults (2000) (40)
Foodborne pathogens in in-line milk filters and associated on-farm risk factors in dairy farms authorized to produce and sell raw milk in northern Italy. (2012) (39)
ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera. (2013) (37)
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 (2018) (36)
L-Asparaginase Lowers Protein C Antigen (1984) (35)
PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA (2013) (34)
Quantitative risk assessment of verocytotoxin-producing Escherichia coli O157 and Campylobacter jejuni related to consumption of raw milk in a province in Northern Italy. (2012) (34)
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms (2018) (33)
Inefficacy of intravenous immunoglobulin in patients with low‐risk thrombotic thrombocytopenic purpura/hemolytic‐uremic syndrome (1992) (33)
Prefibrotic myelofibrosis: treatment algorithm 2018 (2018) (32)
Interaction between platelets and lupus anticoagulant (1988) (31)
Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients. (2013) (30)
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results (2012) (30)
Thrombocytopenia in the antiphospholipid syndrome: pathophysiology, clinical relevance and treatment. (1996) (30)
A frameshift mutation leading to type 1 antithrombin deficiency and thrombosis. (1990) (29)
How to manage essential thrombocythemia (2012) (28)
Risk factors and prevention of vascular complications in polycythemia vera. (1997) (28)
Maternal Lupus Anticoagulant and Fatal Neonatal Thrombosis (1987) (28)
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis (2014) (27)
Low incidence of bleeding from HIV‐related thrombocytopenia in drug addicts and hemophiliacs: Implications for therapeutic strategies (1990) (27)
Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "Pros" and "Cons". (2012) (27)
Idiopathic erythrocytosis and other non-clonal polycythemias. (2006) (27)
EPIDEMIOLOGICAL, DIAGNOSTIC, THERAPEUTIC AND PROGNOSTIC ASPECTS OF ESSENTIAL THROMBOCYTHEMIA IN RETROSPECTIVE STUDY OF THE GIMMC GROUP IN TWO THOUSAND PATIENTS (1997) (26)
Immunoelectrophoretic evidence of a thrombin‐induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III ‘Vicenza’) (1983) (25)
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (25)
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia (2012) (24)
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: Proceedings from the 6th international post‐ASH symposium (2012) (24)
ASXL1 mutations in primary and secondary myelofibrosis (2012) (23)
Survival of Arcobacter butzleri during production and storage of artisan water buffalo mozzarella cheese. (2013) (23)
Second cancers in MPN: Survival analysis from an international study (2019) (23)
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma (1995) (22)
Evidence-based management of polycythemia vera. (2006) (22)
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis (2019) (22)
Are MPNs Vascular Diseases? (2013) (22)
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (22)
Glucose‐6‐phosphate dehydrogenase deficiency: genetic heterogeneity in Sardinia (1982) (22)
Clinical Trials on Antiphospholipid Syndrome: What is Being Done and What is Needed? (1994) (22)
Apparent Heterozygous Type II Protein C Deficiency Caused by the Factor V 506 Arg to GIn Mutation (1995) (21)
Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk. (2007) (20)
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper (2019) (20)
A guide to oral anticoagulant therapy (1998) (19)
Fibrinogen Bergamo I (Aα16Arg → Cys): Susceptibility Towards Thrombin Following Aminoethylation, Methylation or Carboxamidomethylation of Cysteine Residues (1985) (19)
A Phase 1/2 Study of RAD001, a mTOR Inhibitor, In Patients with Myelofibrosis: Final Results (2010) (19)
Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. (2019) (19)
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO‐criteria and stratified by calendar period of diagnosis (2015) (18)
Clinical Coagulation Laboratory and Oral Anticoagulant Therapy Treatment. Instrumentation and Methodology (1995) (18)
The treatment of polycythaemia vera: an update in the JAK2 era (2007) (18)
Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study (2011) (17)
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study. (2019) (17)
A common point mutation producing type 1A antithrombin III deficiency: AT129 CGA to TGA (Arg to Stop). (1991) (17)
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia. (2001) (17)
Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium (2011) (17)
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera (2018) (17)
Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. (2003) (16)
Antiphospholipid antibodies and necrotizing purpura. (1990) (16)
Immunohistologic Diagnosis of Pseudorabies (Aujeszky's Disease) using Monoclonal Antibodies (1997) (16)
A guide to oral anticoagulant treatment. Recommendations of the Italian federation of anticoagulation clinics (FCSA) (2003) (16)
The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts (2017) (15)
Heparin-induced thrombocytopenia--background and implications for haemodialysis. (1996) (15)
Coinheritance of the HR 2 Haplotype in the Factor V Gene Confers an Increased Risk of Venous Thromboembolism to Carriers of Factor V R 506 Q ( Factor V Leiden ) (1999) (15)
How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy—a GIMEMA MPN WP survey (2020) (15)
COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey (2020) (15)
Rituximab in autoimmune cytopenias: for which patients? (2002) (14)
A guide to oral anticoagulant treatment (1998) (14)
The epidemiology of the antiphospholipid syndrome: Who is at risk? (2001) (14)
Primary antithrombotic prevention in carriers of antiphospholipid antibodies without systemic autoimmune disorders (2012) (13)
INTRAVENOUS GAMMAGLOBULIN, ANTIPHOSPHOLIPID ANTIBODIES, AND THROMBOCYTOPENIA (1988) (13)
Feasibility of a randomized clinical trial for the prevention of recurrent thrombosis in the antiphospholipid syndrome: the WAPS project. Provisional Steering Committee of the Warfarin in Antiphospholipid Syndrome (WAPS) Study. (1996) (13)
Special Issues in Myeloproliferative Neoplasms (2011) (13)
Oral anticoagulant therapy in hemodialysis patients: do the benefits outweigh the risks? (2009) (13)
Aspirin in asymptomatic patients with confirmed positivity of antiphospholipid antibodies? No (2008) (13)
A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy (2011) (13)
A survey study on safety and microbial quality of “gluten-free” products made in Italian pasta factories (2017) (13)
Congenital Resistance to Activated Protein C in Patients with Lupus Anticoagulants: Evaluation of Two Functional Assays (1998) (11)
Antiblastic therapy and thrombosis (1992) (10)
Seasonal Variability of Thermophilic Campylobacter Spp. in Raw Milk Sold by Automatic Vending Machines in Lombardy Region (2016) (10)
Bleeding and thrombosis in acute lymphoblastic leukemia. (1993) (10)
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. (2011) (9)
Behaviour of Salmonella Typhimurium during production and storage of artisan water buffalo Mozzarella cheese (2012) (9)
Direct oral anticoagulants in rare venous thrombosis (2016) (9)
Ruxolitinib in ET: not all MPN are equal. (2017) (9)
Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? (2015) (9)
Preparation of Powdered Infant Formula: Could Product's Safety Be Improved? (2018) (9)
MULTIPLE MYELOME IN A PAIR OF TWINS (1987) (9)
Behaviour of Listeria monocytogenes in packaged water buffalo mozzarella cheese (2011) (9)
Purification of antithrombin ‘Vicenza’: a molecule with normal heparin affinity and impaired reactivity to thrombin (1985) (8)
PO-26 - Whole blood rotational thromboelastometry (ROTEM) to detect hypercoagulability in patients with myeloproliferative neoplasms (MPN). (2016) (8)
Etretinate therapy and thrombocytopenia (1991) (8)
Essential thrombocythemia. (2008) (8)
Essential thrombocythemia. (2005) (7)
Clinical trials in myeloproliferative disorders: looking forward. (2005) (7)
Recurrent thrombosis in patients with polycythemia vera or essential thrombocythemia : efficacy of treatment in preventing rethrombosis in different clinical settings (2006) (7)
Management of essential thrombocythemia. (1999) (7)
Molecular characterisation and biofilm production in Staphylococcusaureus isolates from the dairy production chain in Northern Italy (2019) (7)
A Two-Part Study of Givinostat in Patients with Polycythemia Vera: Maximum Tolerated Dose Definition and Preliminary Efficacy Results (2016) (7)
Expertise-Based Management in Essential Thrombocythemia and Polycythemia Vera (2007) (7)
Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin , Protein C , Protein S Deficiency , or Activated Protein C Resistance (1999) (7)
Prophylactic platelet transfusion in acute leukemia: which threshold should be used. (1998) (6)
Study of Growth Potential of Listeria Monocytogenes in Low Fat Salami: An Innovative Italian Meat Product (2014) (6)
Antiphospholipid antibodies and melanoma: a link? (1992) (6)
The management of ‘low‐risk’ and ‘intermediate‐risk’ patients with primary thrombocythaemia (1999) (6)
IgM gammopathy and the lupus anticoagulant syndrome in habitual aborters. (1986) (6)
Two novel (R(−11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindreds (1996) (5)
Contamination of Poultry Meat with Salmonella infantis should be considered a Risk for Food Safety? (2019) (5)
Leukocytosis as an Independent Risk Factor for Thrombosis in Polycythemia Vera. (2006) (5)
Low Prevalence of JAK2 Val617Phe Mutation in Patients with Idiopathic Erythrocytosis. (2005) (5)
Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data. (2006) (5)
Self-testing and self-monitoring of oral anticoagulant therapy: consensus of the Italian Federation of Anticoagulation Clinics (2003) (5)
A retrospective study on oral anticoagulant prophylaxis in 103 Italian patients with hereditary thrombophilia and thrombosis (1990) (5)
Two unlinked cases of foodborne botulism in Italy at the beginning of 2010. (2011) (4)
Long Term Follow up of a Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm (2015) (4)
Antiphospholipid Antibodies and Associated Clinical Manifestations. (1996) (4)
FLOQSwab™: Optimisation of Procedures for the Recovery of Microbiological Samples from Surfaces (2016) (4)
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin (2019) (4)
Investigation and Follow-Up of a Staphylococcal Food Poisoning Outbreak Linked to the Consumption of Traditional Hand-Crafted Alm Cheese (2020) (4)
A Structural Study on the Listeria Monocytogenes Internalin A—Human E-cadherin Interaction: A Molecular Tool to Investigate the Effects of Missense Mutations (2020) (4)
How Epidemiology of Polycythemia Vera Has Changed in the Last 10 Years: Results From the Whole Prospective Cohort of Patients in Cyto-PV Trial As Compared with Eclap Prospective Cohort (2012) (4)
European leukemianet-integration of the leading national leukemia networks (CML, AML, ALL, CLL, MDS, CMPD) another interdisciplinary partner groups in Europe (2007) (4)
Silter Cheese, a Traditional Italian Dairy Product: A Source of Feasible Probiotic Strains (2015) (4)
Multiple myeloma in a pair of twins. (1987) (4)
[Antiphospholipid antibody syndrome]. (1999) (3)
The HDAC INHIBITOR ITF2357 MODULATES KEY HEMATOPOIETIC GENES in JAK2V617F CELLS From MYELOPROLIFERATIVE Neoplasm PATIENTS (2010) (3)
Chronic myeloid disorders, excluding CML (2004) (3)
Abnormal leukocyte scattergrams and immature platelet fraction on Sysmex XN-9000 analyzer: a new diagnostic tool for altered megakaryopoiesis? (2017) (3)
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative (2019) (3)
A Phase 2 Study Of Ruxolitinib In Patients With Splanchnic Vein Thrombosis Associated With Myeloproliferative Neoplasm. Preliminary Results (2013) (3)
Recombinant Versus High-sensitivity Conventional Thromboplastin: A Randomized Clinical Study in Patients on Oral Anticoagulation (1994) (3)
Infant Botulism: Checklist for Timely Clinical Diagnosis and New Possible Risk Factors Originated from a Case Report and Literature Review (2021) (3)
[Clinical significance and predictive value of laboratory tests in thrombosis associated with antiphospolipid antibodies]. (1997) (3)
Two novel (R(-11)C; T394D) and two repeat missense mutations in the protein C gene associated with venous thrombosis in six kindreds. (1996) (3)
Essential thrombocytemia and ischemic stroke: Report of six cases (1994) (3)
Determinants of thrombin generation in gynaecological malignancies (2016) (2)
Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms (2018) (2)
The Management of Essential Thrombocythaemia. (1997) (2)
Increased Platelet Thrombus Formation Under Flow Condition In Myeloproliferative Neoplasms (MPN) (2013) (2)
Thrombotic and Hemorrhagic Complications after Surgery in Patients with Essential Thrombocythemia and Polycythemia Vera. (2006) (2)
DYNAMICS OF LISTERIA MONOCYTOGENES, SALMONELLA TYPHIMURIUM ESCHERICHIA COLI O157: H7 DURING THE PRODUCTION OF ‘NDUJA (2011) (2)
Givinostat for the treatment of polycythemia vera (2014) (2)
A Phase 2 Study of Ruxolitinib in Patients with Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasm: A Study from the AGIMM Group (2014) (2)
Platelet Adhesion Under Flow Condition in Patients with Essential Thrombocythemia (ET) and Polycythemia Vera (PV): Analysis According to the Mutational Status (2015) (2)
Hereditary dysfunctional protein C (protein C "Bergamo II") diagnosed by a rapid assay. (1987) (2)
A Large-Scale Trial Testing the Intensity of Cytoreductive Therapy to Prevent Cardiovascular Events in Patients with Polycythemia Vera (CYTO-PV trial) (2012) (2)
Molecular basis of protein C deficiency in five patients with thrombophilia. (1993) (2)
Association between lupus anticoagulant and epilepsy (1987) (1)
[Clinical research at the European LeukemiaNet]. (2006) (1)
A Listeria monocytogenes ST325 clone is widespread in the Lombardy Region dairy processing plants (2020) (1)
Risk Factors for Thrombosis Among 1,545 Patients with Polycythemia Vera: An International Study. (2012) (1)
Risk Factors for Secondary Cancer in a Case-Control Study on 1,259 Patients with Myeloproliferative Neoplasms (2018) (1)
Management of special conditions in patients on vitamin K antagonists (2012) (1)
Platelets in Thrombotic and Non-thrombotic Disorders: Thrombocytosis and thrombocythemia (2002) (1)
Microparticle-Associated Thrombin Generation and Procoagulant Activity Is Increased In Patients with Essential Thrombocythemia (2010) (1)
Ongoing randomized clinical trials for the treatment of thrombosis in the antiphospholipid syndrome (2001) (1)
Is SARS-CoV-2 a Concern for Food Safety? A Very Low Prevalence from a Food Survey during the COVID-19 Pandemic in Northern Italy (2022) (1)
Prefibrotic myelofibrosis: treatment algorithm 2018 (2018) (1)
Short and Long-Term Risk of Major Cardiovascular Events after Ischemic Stroke or Transient Ischemic Attack in Myeloproliferative Neoplasms (2017) (1)
PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. (2016) (1)
Foodborne botulism survey in Northern Italy from 2013 to 2020: Emerging risk or stable situation? (2022) (1)
Neurosarcoidosis, stroke and antiphospholipid antibodies: a case report (1996) (1)
Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls (2019) (1)
ADP-Induced Whole Blood Aggregometry and Platelet-Associated Thrombin Generation (TG) In Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Patients (2010) (1)
Contents, Vol. 180, 1990 (1990) (0)
Intrinsic and method-induced variation of the bleeding time and related parameters (2007) (0)
Listeria monocytogenes behaviour in gastronomy food: rice salad. (2010) (0)
Dynamic of several pathogens in artificially contaminated Salame Piacentino DOP. (2009) (0)
Unanswered questions in polycythaemia vera (2007) (0)
Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms (2018) (0)
Antiphospholipid antibodies and intravascular thrombosis. (1994) (0)
expert panel primary myelofibrosis: recommendations from an ad hoc international diagnostic criteria for polycythemia vera, essential thrombocythemia, and Proposals and rationale for revision of the World Health Organization (2013) (0)
High-Sensitivity C-Reactive Protein (hs-CRP) and Pentraxin 3 (PTX3) Are Increased in Essential Thrombocythemia and Polycythemia Vera. (2009) (0)
Shelf-life assessment of Modena DOP raw ham sold in vacuum packed pieces. (2010) (0)
STEC prevalence in raw milk cheese produced in LombardiaBarbara Bertasi (2016) (0)
polycythemia vera or essential thrombocythemia Clinical profile of homozygous JAK2 617V>F mutation in patients with (2013) (0)
ESSENTIAL THROMBOCYTHEMIA (ET) AND POLYCYTHEMIA VERA (PV) PATIENTS SHOW AN INCREASED THROMBUS FORMATION IN A DYNAMIC MODEL OF PLATELET ADHESION (2017) (0)
Gluten quantification in gluten-free food for celiac people in Lombardy and Emilia Romagna - Italy (2022) (0)
PREVALENCE OF A N T I T H R O M B I N III DEFICIENCY IN BLOOD DONORS SELECTED FOR PERSONAL OR FAMILIAL HISTORY OF VENOUS THROMBOSIS (0)
Management of Patients with Essential Thrombocythemia (2009) (0)
OCCURRENCE OF LISTERIA MONOCYTOGENES IN READY TO EAT FOOD SAMPLES COLLECTED BY LOMBARDY REGION HEALTH AUTHORITIES IN 2009-2010 (2012) (0)
Cerebral ischemia in a patient with protein S deficiency and carotid stenosis (1994) (0)
Abnormal reactivity with thrombin of a new variant of dysfunctional antithrombin (AT ‘Vicenza’) (1984) (0)
(IPSET-thrombosis) essential thrombocythemia - thrombosis in World Health Organization Development and validation of an International Prognostic Score of (2013) (0)
Botulinum toxin inactivation during cooking of artificially contaminated potato gnocchi. (2009) (0)
Similar Rate of Thrombosis in Essential Thrombocythemia and Polycythemia Vera Patients after Stratification for JAK2 V617F Allele Burden. (2008) (0)
essential thrombocythemia, polycythemia vera, and myelofibrosis Long-term survival and blast transformation in molecularly annotated (2014) (0)
PO-52 Determination of thrombin generation (TG) and procoagulant activity (PCA) expressed by circulating microparticles (MP) in essential thrombocythemia (ET) patients (2010) (0)
Response: Thrombocytosis in low-risk ET patients (2008) (0)
[Management of quantitative and qualitative platelet defects]. (1999) (0)
PB2192 GLOBAL COAGULATION CAPACITY OF ESSENTIAL THROMBOCYTHEMIA PATIENTS BY ROTEM ANALYSIS ADJUSTED FOR PLATELET COUNT CORRELATES WITH THROMBOTIC RISK CLASS (2019) (0)
Newly Designed Primers for the Sequencing of the inlA Gene of Lineage I and II Listeria monocytogenes Isolates (2022) (0)
Leucocytosis is a risk factor for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia (2009) (0)
Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor. (2006) (0)
A frameshift mutation in the antithrombin gene leading to type 1 deficiency and thrombosis (1990) (0)
Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms (2018) (0)
Thrombophilia as a polygenic disease: A study of 24 genetically characterized protein C deficient probands with thrombosis (1999) (0)
Monitoring of Vibrio spp. in edible molluscs, lamellibranchia and sea water [Conference poster]. (2012) (0)
Polycythaemia vera (2020) (0)
Successful treatment with heparin of cerebral vein thrombosis in young patients (1992) (0)
Quantifying LAB populations in raw milk and dairy products through a Real Time PCR assay (2018) (0)
Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018 (2018) (0)
Intestato parente mortuo adgnatis defertur tutela: sul principio d'identità fra eredità e tutela. (2016) (0)
JAK2V617F Mutation and Thrombosis History Are Determinants of Mean Platelet Volume (MPV) in Essential Thrombocythemia Patients (2016) (0)
Dynamics of several pathogen microorganisms in packaged water-buffalo mozzarella cheese. (2010) (0)
Behavioural dynamics of several pathogen microorganisms during processing and ripening of Bagòss cheese. (2009) (0)
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting (2018) (0)
Mycobacterium bovis experimental infection in three calves (1999) (0)
Biofilm formation by different genotypes of dairy Staphylococcus aureus isolates from Northern Italy (2018) (0)
Current Treatment Approaches of Polycythemia Vera (2006) (0)
Risk Factors for Thrombosis in WHO-Defined Early/Prefibrotic Myelofibrosis: An International Study of 264 Patients, (2011) (0)
Predicting the survival of Salmonella spp. in Italian salami [Calabria; Lombardy] (2005) (0)
Diagnosis of human botulism in Northern Italy during 2012-2016Guido Finazzi (2017) (0)
Sensitivity and Specificity of Laboratory Parameters to Detect Early/Prefibrotic Myelofibrosis in 857 Patients with Essential Thrombocythemia. A Diagnostic Algorithm (2011) (0)
Integrated veterinary-medical activity on characterization of shigatoxin producing Escherichia coli (2019) (0)
The telomerase inhibitor imetelstat in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF) previously treated with Janus kinase (JAK) inhibitor: A phase 2, randomized study. (2016) (0)
Hydroxyurea: the comparator in studies with new anti-JAK2 inhibitors (2009) (0)
Recurrent Venous Thrombosis in Patients with Polycythemia Vera and Essential Thrombocythemia (2007) (0)
Therapy of Polycythemia Vera and Essential Thrombocythemia (2011) (0)
Prevalence of antithrombin III deficiency in blood donors selected for personal or familial history of venous thrombosis (1985) (0)
WAPS (warfarin in the antiphospholipid syndrome) study Clinical significance of different antiphospholipid antibodies in the (2013) (0)
Foodborne outbreak of gastroenteritis caused by Staphyilococcal enterotoxin in Northern Italy (2018) (0)
Clotting system activation in patients with cancer undergoing major surgery: The role of heparin prophylaxis (1992) (0)
Pregnancies in Patients with Philadelphia Negative Chronic Myeloproliferative Disorders: Interim Report of the European LeukemiaNet Data Base (2008) (0)
Rebuttal to the Letter to the Editor by Dr. A. Girolami (1993) (0)
POINT MUTATIONS PRODUCING TYPE-1A ANTITHROMBIN-III DEFICIENCY (1991) (0)
The newly diagnosed patient with essential thrombocythemia (2016) (0)
thrombocythemia: a retrospective survey Post-surgery outcomes in patients with polycythemia vera and essential (2013) (0)
PS1468 IMPACT OF CYTOREDUCTIVE DRUGS ON SECOND CANCER IN MYELOPROLIFERATIVE NEOPLASMS (2019) (0)
JAK2 Val617Phe Mutation Correlates with the Risk of Thrombosis in Patients with Essential Thrombocythemia. (2005) (0)
Preclinical Advances in the Pathogenesis and Therapy of Myeloproliferative Neoplasms TET 2 (2012) (0)
PO-28 Increased thrombin generation (TG) potential of platelets from myeloproliferative neoplasms (2010) (0)
Organization of a Randomized Clinical Trial for the Prevention of Recurrent Thrombosis in the Antiphospholipid Syndrome: the WAPS Project (Warfarin in Antiphospholipid Syndrome) (1998) (0)
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases (2018) (0)
Different effect of hydroxyurea and phlebotomy on prevention of arterial and venous thrombosis in Polycythemia Vera (2018) (0)
Epidemiological Study of Salmonella spp. Strains Isolated in Lombardia from 2012-2016 (2017) (0)
Effects of Antiplatelet Treatment with Aspirin (ASA) on Platelet Reactivity in Patients with Essential Thrombocythemia (2016) (0)
Abstract citation ID: ckac131.237 Gluten quantification in gluten-free food for celiac people in Lombardy and Emilia Romagna-Italy (2022) (0)
LA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI (1999) (0)
Final Analysis at 5 Years Follow up of Patients with MPN-Associated Splanchnic Vein Thrombosis Treated with Ruxolitinib in a Phase 2 Study (2019) (0)
[Congenital deficiency of antithrombin III]. (1990) (0)
enrolled in a prospective observational study Acute leukemia in polycythemia vera: an analysis of 1638 patients (2013) (0)
Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients. (2021) (0)
Management of Patients with Polycythemia Vera (2009) (0)
Behaviour of Listeria monocytogenes in chunked or sliced seasoned Bresaola della Valtellina IGP. (2009) (0)
Behaviour of Listeria monocytogenes in delicatessen products: seafood salad. (2010) (0)
PF671 RATE OF THROMBOSIS IN CONTEMPORARY PATIENTS WITH POLYCYTHEMIA VERA UNDER HYDROXYUREA REMAINS EXCEEDINGLY HIGH. RESULTS OF SYSTEMATIC REVIEW AND METANALYSIS (2019) (0)
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms (2018) (0)
Integrated monitoring of AMR and enterotoxins genes of S. aureus isolated in Lombardy (2022) (0)
Optimization of Microbiological Recovery from Surfaces for Environmental Monitoring (2016) (0)
Calreticulin Mutation Does Not Modify the International Prognostic Score for Predicting the Risk of Thrombosis Among 1,150 Patients with Essential Thrombocythemia (2014) (0)
Erratum: Platelet‐induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera (2011) (0)
CIABUSCOLO: PROCESS AND PRODUCT STANDARD EVALUATION. PRELIMINARY STUDY (2008) (0)
Gene mutations in twenty-six families with protein C deficiency (1995) (0)
CANCER-ASSOCIATED THROMBOTIC DISEASE Myeloproliferative neoplasms and thrombosis (2017) (0)
P olycythemia vera (2008) (0)
Listeria monocytogenes behaviour in gastronomy food: octopus and potato salad. (2010) (0)
international expert panel and primary myelofibrosis: recommendations from an ad hoc diagnostic criteria for polycythemia vera, essential thrombocythemia, Proposals and rationale for revision of the World Health Organization (2009) (0)
Antithrombin III and Other Natural Inhibitors of Coagulation (1985) (0)
Acquired thrombophilia: antiphospholipid syndrome and essential thrombocythemia (2002) (0)
Behaviour of Salmonella Typhimuriumduring production and storage of artisan water buffalo (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Guido Finazzi?

Guido Finazzi is affiliated with the following schools: